52% reduction in th e risk of relapse with IWILFIN 

Primary Endpoint: EFS 

EFS is defined as the period from the last day of immunotherapy until the first occurrence of relapse, progressive disease, secondary cancer, or death1,14 

In supplementary analyses, the reduced risk of relapse for patients taking IWILFIN ranged from 57% to 41%. 

68% reduction in the risk of death with IWILFIN

Secondary Endpoint: OS 

OS is defined as as the first day of administration of IWILFIN until death14 

In supplementary analyses, the reduced risk of death for patients taking IWILFIN ranged from 71% to 55%.